#ACR22 Abstr#L07 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without). No major safety. Phase 3 in US is in progress. Would be historic! @RheumNow #ACRBest https://t.co/8wL2tkA8ym